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Abstract 
Protein-losing enteropathy (PLE) is a debilitating potential complication of ulcerative colitis 
(UC). We report a case of PLE in a 26-year-old male patient with UC. The patient lost 
50 pounds in the setting of a UC flare and was found to have an albumin level of 1.2 g/dl. 
Although the patient’s UC was clinically controlled with steroids, the weight loss and 
hypoalbuminemia persisted with the patient’s course complicated by development of deep 
vein thrombosis and pulmonary embolism. The diagnosis of PLE was confirmed with 
measurement of stool alpha-1-antitrypsin clearance. The patient’s condition significantly 
improved following procto-colectomy. 
 
Introduction 
Ulcerative colitis (UC), first described in 1875 by Sir Samuel Wilks, has been 
associated with a plethora of gastrointestinal and extra-intestinal manifestations. UC, a 
major type of inflammatory bowel disease, is characterized by colonic inflammation 
that starts in the rectum and can extend proximally to involve various lengths of colon. 
The inflammation in UC is continuous and limited to the mucosal layer of the bowel 
wall. In contrast, Crohn’s disease, the other major form of inflammatory bowel disease, 
can affect any part of the intestinal tract, often has skip lesions, and causes transmural 
inflammation. UC typically presents clinically as bloody diarrhea with associated 
abdominal pain, tenesmus, and urgency. Patients with UC may also experience various 
extra-intestinal manifestations including pyoderma gangrenosum, uveitis, migratory 
arthritis and primary sclerosing cholangitis. Medical treatment of UC can employ oral 
or rectal 5-aminosalicylates, oral or rectal glucocorticoids, immunomodulators such as 
azathioprine and 6-mercaptopurine, or biologic agents such as infliximab and 
adalimumab. Colectomy can be a potentially curative procedure in severe cases.  
Case Rep Gastroenterol 2012;6:177–182 
DOI: 10.1159/000338191 
Published online: 
April 11, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
 
178 
One of the most devastating complications of UC, protein-losing enteropathy (PLE), 
can further deteriorate the health and well-being of a subset of patients with UC. PLE 
involves the loss of plasma proteins through the bowel wall into the intestinal tract and 
can lead to malnutrition, edema, fatigue and weight loss. The association of UC and PLE 
has been previously described, usually related to severe ulceration of the colonic 
mucosa or concurrent infection, with agents such as cytomegalovirus [1]. Here, we 
report a case of existing UC and severe PLE that persisted after the acute clinical phase 
of UC had been controlled and the procto-colitis symptoms had improved with medical 
therapy. Although the inflammatory process appeared to be regressing, the loss of 
protein worsened, prompting this case report and a review of the current 
understanding of the association of UC and PLE. 
Case Report 
The patient, a 33-year-old male, was diagnosed with ulcerative colitis in 2001 at the age of 26 after 
presenting with 2 weeks of mid-abdominal pain and 5–6 loose bowel movements daily that were 
mixed with mucus and blood. His symptoms improved after 1 month of treatment with mesalamine 
tablets, with a decrease in bowel movements to 1–2 per day without blood or mucus. He was 
subsequently changed to balsalazide and continued on this medication for 4 years with good 
symptomatic control. The patient’s other past medical history was significant only for kidney stones. 
Both of the patient’s parents had diabetes and there was no family history of inflammatory bowel 
disease. The patient was married and worked in advertising. He used to smoke cigarettes regularly 
but stopped smoking a few months prior to being diagnosed with UC. He drank alcohol rarely and 
never used illicit drugs. There were no known drug allergies. 
The patient was changed to Asacol in early 2005 after needing intermittent courses of steroid 
enemas for mild UC flares characterized by mild diffuse abdominal discomfort and more loosely 
formed stool mixed with blood. He did not experience another UC flare until 2007 when he had a 
more severe UC flare in which he had 3–4 bloody bowel movements a day with moderate to severe 
abdominal pain and significant fatigue. His condition significantly improved with 40 mg of prednisone 
daily, which was tapered off over the course of 4 months. Between 2001 and 2008, the patient was 
never hospitalized and maintained a weight of 170 pounds. 
His condition deteriorated, however, in early 2008 with increased bleeding and frequency of 
bowel movements. He was constantly fatigued, had 5–6 bloody bowel movements daily, and suffered 
from frequent diffuse cramping pain in the abdomen. His weight decreased to 120 pounds, 
representing a drop in his body mass index from 28 to 20, and he was so debilitated that he was 
unable to work. On physical exam, the patient was extremely thin, had diffuse mild to moderate 
abdominal tenderness and 1+ pedal edema bilaterally. Laboratory testing showed iron deficiency 
anemia with a hemoglobin of 7.1 g/dl. The patient was again started on oral steroids. A colonoscopy at 
that time revealed retrograde progression of the inflammatory process from the rectum to the 
transverse colon, with development of pseudopolyps. There was no evidence of dysplasia on multiple 
biopsies from 2006 through 2008. During this period, his course was complicated by a deep vein 
thrombosis of the left lower extremity and a pulmonary embolus necessitating treatment with 
warfarin. Although the oral steroids alleviated his symptoms with resolution of abdominal pain and 
improvement in frequency of bowel movements to 2–3 daily with only occasional blood, the patient’s 
serum albumin fell from 4.0 to 1.2 g/dl. 
Repeat colonoscopy revealed improvement of the mucosal disease, with no evidence of dysplasia 
on biopsy. No inclusion bodies consistent with cytomegalovirus colitis were noted on pathologic 
evaluation. Stool testing was also negative for Clostridium difficile toxin. Even with endoscopic 
improvement, the patient’s serum albumin continued to be <2 g/dl and he was unable to regain 
weight from his 50 pound weight loss, leading to a diagnosis of PLE. PLE was confirmed by an 
elevated stool alpha-1-antitrypsin (A1AT) clearance of 162 ml/24 h, which was greater than 5 times 
the upper limit of normal of the testing laboratory. He remained severely debilitated and emaciated 
even though his UC symptoms were controlled. Due to his persistent weakness and PLE, the patient  
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underwent a 3-stage restorative procto-colectomy, each stage preceded by insertion of a retrievable 
vena cava filter to prevent pulmonary emboli. At the time of surgery the patient’s UC regimen 
consisted of Asacol and mesalamine enemas. He underwent closure of his ileostomy and construction 
of a J-pouch 3 months following his initial surgery and quickly regained weight, which he has 
maintained with a most recent weight of 200 pounds. The patient has returned to a productive life 
with an albumin of 4.2 g/dl, 4–5 non-bloody bowel movements daily with no leakage, and no further 
evidence of PLE. Although the last colonoscopy several months prior to the procedure demonstrated 
improvement of the inflammatory process, the resected colon did demonstrate active UC with 
ulceration and extensive inflammatory polyposis from the rectum to the cecum, measuring 0.5–3.0 cm 
in greatest dimension, as well as one giant inflammatory polyp (fig. 1). There was no evidence of 
dysplasia. 
Discussion 
There is rapidly accumulating evidence that the etiology of UC is related to both 
genetic and environmental factors. Genetic associations have been shown for the MHC 
locus HLA class II alleles. More recently, the gene encoding the interleukin-23 receptor 
has been associated with susceptibility to developing UC [2]. The multi-drug resistance 
gene MDR1 has also been implicated as a genetic factor in the development of disease. 
Intraluminal antigens are of significance as evidenced by a relationship between UC 
and bacterial flora including Bacteroides and Enterobacteriaceae species. Conversely, 
cigarette smoking and appendectomy are associated with a decreased incidence of UC. 
In spite of our growing understanding of the disease, there is yet to be a unified, 
definitive etiology of UC [3]. Recently developed diagnostic strategies, including the 
detection of fecal and serologic markers and the use of wireless capsule endoscopy, 
have expanded our understanding of UC. However, in the absence of specific 
biomarkers, the definition of UC remains based on clinical, endoscopic and pathologic 
criteria. Until further specificity regarding pathogenesis is elucidated, specific therapies 
for UC remain elusive. Further, an overlap of pathophysiologic processes between UC, 
post-infectious irritable bowel syndrome, Crohn’s disease and other colitides may 
hinder new therapeutic approaches. 
PLE occurs in multiple clinical disease states, all resulting from increased mucosal 
permeability and excessive transmucosal loss of plasma proteins into the intestinal 
lumen because of mucosal damage, inflammatory ulceration, or leakage from 
obstructed lymphatic channels. Interestingly, inflammatory polyposis may contribute 
to PLE in UC by increasing mucosal surface area and cell turnover [4]. The etiologies of 
PLE transverse a wide range of conditions including, but not limited to, amyloidosis, 
viral enteritides, eosinophilic gastroenteropathies, systemic lupus erythematosis, 
Ménétrier disease, sarcoidosis, schistosomiasis, intestinal lymphangiectasia, Whipple’s 
disease, non-tropical sprue, UC, superior cava syndrome, bacterial overgrowth, 
C. difficile colitis, giardiasis, congestive heart failure, lymphoma and leukemia, and 
post-Fontan procedure for congenital atresia of the tricuspid valve [5]. 
In 1949, Albright et al. [6] demonstrated an increase in protein turnover in patients 
with PLE. In 1958, Citrin et al. [7] were the first to use radiolabeled tracers to reveal the 
actual loss of proteinaceous fluid into the gastrointestinal tract. More recently Tc-99m 
dextran has been used for the same purpose [8]. In PLE, the loss of protein through the 
gastrointestinal tract (normally <2% of the total serum protein pool) can be as high as 
60% of the total albumin pool, resulting in a severe catabolic state. The serum proteins  
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most often affected by this leakage are those with long half-lives, like albumin, many 
immunoglobulins and ceruloplasmin. In response to the gastrointestinal losses, the 
liver can slightly increase the production of rapidly turned-over proteins such as 
transthyretin (prealbumin), immunoglobulin E, and insulin [9]. Lower concentrations 
of other substances like lipids, iron and other trace elements can be seen, as well as 
lymphopenia, especially when lymphatic obstruction is present. 
PLE can be caused by conditions with or without mucosal erosions. UC and Crohn’s 
disease are both inflammatory conditions of the gastrointestinal tract that cause 
erosions and can lead to PLE. It is thought that protein loss in these conditions is due to 
enhanced leakage of protein-rich fluids across an ulcerated or eroded mucosal lining. 
The severity of the condition most often correlates to the extent of protein loss [10]. In 
fact, the severity of protein loss had been suggested to be an indicator of the severity of 
inflammatory bowel disease. This correlation is usually confirmed with fecal A1AT 
clearance, now considered the test of choice to verify the diagnosis of PLE [11]. 
Our patient certainly demonstrated clinical evidence of PLE with a persistently 
decreased serum albumin and a markedly elevated A1AT clearance. Fischbach et al. 
[12] demonstrated that measurement of A1AT levels in the stool was a reliable and 
simple test for PLE that does not require radiolabeled tracers. A1AT is a protein 
similar in size to albumin that is produced by the liver and eliminated through the 
gastrointestinal tract. It is neither degraded nor absorbed in the intestine, allowing it to 
be excreted intact and detected in stool [5]. Of note, A1AT is broken down in the acidic 
environment of the stomach when pH is <3, and if a gastric source of protein loss is 
suspected, patients should be given a proton pump inhibitor prior to measuring A1AT 
clearance [13]. This approach has identified various conditions that have subclinical 
PLE as a component of the disease process. Also of note is the fact that our patient, 
although clinically improved on corticosteroids, continued to have pathological 
evidence of ongoing colorectal inflammation, placing him in the category of patients 
with PLE and mucosal erosive disease. Evaluation with urinary excretion studies 
distinguished the hypoproteinemia as intestinal rather than renal in origin. Identifying 
that the protein loss is enteric in origin is essential, carefully eliminating kidney and 
skin as sources of the problem. A clue to the enteric source of the protein loss is that 
unlike skin and the gastrointestinal tract, renal loss of protein is usually limited to small 
molecules like albumin, whereas the former are much less selective, as evidenced by 
A1AT loss. Since the liver is responsible for protein synthesis, liver synthetic function 
must also be assessed in hypoalbuminemic states to make a diagnosis of PLE although 
stool A1AT clearance would not be elevated in liver disease. 
Treatment of PLE in UC usually aims at controlling the underlying inflammatory 
process. As demonstrated by this case, even when symptomatically improved, 
persistence of inflammation can still lead to massive loss of protein into the 
gastrointestinal tract. Treatment options are limited. Anecdotal reports of the use of 
intravenous heparin and octreotide have been published [14, 15]. However, in UC the 
mainstay of treatment is to treat the underlying inflammation, even if subclinical.  
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Conclusion 
The incidence and prevalence of PLE in UC remains unknown. Although the etiology 
appears to be mucosal disruption, PLE can occur in UC even if the symptomatic 
manifestations of the disease improve with acute treatment. The persistence of 
underlying inflammation may allow for the development of PLE in a small number of 
patients as the primary manifestation of UC. This complication may be debilitating, and 
its presence may be a sufficient indication for surgical intervention. 
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Fig. 1. Histopathology from the patient’s procto-colectomy. a Photograph of gross specimen showing 
inflammatory polyposis and one giant inflammatory polyp measuring 6.5 × 4.5 × 3.5 cm located 2 cm 
from the ileocecal valve. The distal 12 cm of the specimen is largely free of pseudopolyps with 
edematous changes. b Representative H&E slide of colon at 40× magnification demonstrating severe 
active idiopathic UC. 
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